Listar Grupos de investigación por autor "Pandha, Hardev S."
Mostrando ítems 1-1 de 1
-
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
De Bono, Johann S.; Piulats, Josep María; Pandha, Hardev S.; Petrylak, Daniel P.; Saad, Fred; Antón-Aparicio, Luis M.; Sandhu, Shahneen K.; Fong, Peter; Gillessen, Silke; Hudes, Gary R.; Wang, Tao; Scranton, Judith; Pollak, Michael N. (American Association for Cancer Research, 2014-02-17)[Abstract] PURPOSE: Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. This phase II trial randomized chemotherapy-naïve ...